

PUBBLICAZIONI

1. Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. *Int J Radiat Oncol Biol Phys* 2016; 94 (4): 783 – 91
2. Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Fare' E, Magni M, Piva L, **Matteucci P**, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. *Ann Oncol.* 2015; 26 (1): 167 – 72
3. Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, Di Nicola M, Fare' E, Raggi D, Magni M, **Matteucci P**, Longoni P, Milanesi M, Paterno' E, Ravagnani F, Arienti F, Nicolai N, Salvioni R, Carlo-Stella C, Gianni AM. Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. *Clin Genitourin Cancer.* 2014; 12 (3): 196 – 202

4. Magni M, Di Nicola M, Patti C, Scime' R, Mule' A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, **Matteucci P**, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Bone Marrow Transplant. 2014; 49 (4): 485 – 91
5. Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, **Matteucci P**, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. J Clin Oncol. 2013; 31 (23): 2974 – 6
6. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, **Matteucci P**, Marchiano' A, Lanocita R, Farina L, Doderò A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol. 2012; 158 (1): 108 – 19
7. Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, **Matteucci P**, Magni M, Devizzi L, Valagussa P, Gianni AM. Long-term results of high-dose chemotherapy with

- autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma. 2010; 51 (7): 1251 – 9
8. Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, **Matteucci P**, Gianni AM. Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplant. 2010; 45 (6): 1119 – 20
9. Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, **Matteucci P**, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM. Radioimmunotherapy and secondary leukemia: a case report. Leuk Res. 2010; 34 (1): 1 - 4
10. Di Nicola M, Zappasodi R, Carlostella C, Mortarini R, Pupa SM, Magni M, Devizzi L, **Matteucci P**, Baldassari P, Ravagnani, F, Cabras A, Anichini A, Gianni AM. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009; 113 (1): 18 – 27
11. Magni M, Di Nicola M, Carlo-Stella C, **Matteucci P**, Devizzi L, Tarella C, Benedetti F, Martelli M, Patti C, Parvis G, Rambaldi A, Barbui T, Gianni AM. High-dose sequential chemotherapy

- and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant. 2009; 43 (6): 509 – 11
12. Devizzi L, Guidetti A, Tarella C, Magni M, **Matteucci P**, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol. 2008; 26 (32): 5175 - 82
13. Corradini P, Doderò A, Farina L, Fanin R, Patriarca F, Miceli R, **Matteucci P**, Bregni M, Scimé R, Narni F, Pogliani R, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21(11): 2316 – 23
14. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca L, Astolfi M, **Matteucci P**, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C. Rituximab induces effective clearance of minimal residual disease in

- molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant. 2006; 12 (12): 1270 – 6
15. Bengala C, Zamagni C, Pedrazzoli C, **Matteucci P**, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF: Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006; 94 (7): 1016 - 20
16. **Matteucci P**, Carlo-Stella C, Di Nicola M, Magni M, Guidetti A, Marchesi M, Gianni AM. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Haematologica 2006; 91 (2): 255 - 7
17. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, **Matteucci P**, Guidetti A, Gandola L, Gianni AM. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt' s lymphoma in adults. Br J Haematol. 2004; 126 (6): 815 - 20
18. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, **Matteucci P**, Formelli F, Ravagnani F, Corradini P, Gianni AM. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and

- collection of CD34+ cells in poor mobilizers. Blood 2004; 103 (9): 3287 - 95
19. Di Nicola M, Napoli S, Anichini A, Mortarini R, Romagnoli R, Magni M, **Matteucci P**, Baldassarri P, Bersani I, Carlo-Stella C, Gianni AM. Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. Haematologica 2003; 88 (12): 1396 - 404
20. Magni M, Di Nicola M, Carlo-Stella C, **Matteucci P**, Lavazza C, Grisanti S, Bifulco C, Pilotti S, Papini D, Rosai J, Gianni AM. Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes; evidence for a common precursor. Leuk Res 2002; 26 (12): 1131 - 3
21. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedé P, Bondesan P, Magni M, **Matteucci P**, Gallamini A, Pileri A, Gianni AM. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant. 2002; 30 (11): 725 - 32
22. **Matteucci P**, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM. Leukoencephalopathy and papovavirus infection

- after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100 (3): 1104 - 5
23. Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, **Matteucci P**, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99 (10): 3838 - 43
24. Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, **Matteucci P**, Grisanti S, Valagussa P, Bonadonna G, Gianni AM. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin' s disease. Eur J Haematol Suppl. 2001; 64: 51 - 5
25. Magni M, Di Nicola M, Devizzi L, **Matteucci P**, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96 (3): 864 - 9
26. Perfetti V, Ubbiali P, Magni M, Colli Vignarelli M, Casarini S, **Matteucci P**, Gianni AM, Merlini G. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplant. 1999; 23 (4): 323 - 7

27. Ravagnani F, Siena S, De Reys S, Di Nicola M, Notti P, Giardini R, Bregni M, **Matteucci P**, Gianni AM, Pellegris G. Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. Transfusion 1999; 39 (1): 48 - 55
28. Di Nicola M, Siena S, Bregni M, Longoni P, Magni M, Milanesi M, **Matteucci P**, Mortarini R, Anichini A, Parmiani G, Drexler I, Erfle V, Sutter G, Gianni AM. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther 1998; 5 (6): 350 - 6
29. Bregni M, Shammah S, Malaffo F, Di Nicola M, Milanesi M, Magni M, **Matteucci P**, Ravagnani F, Jordan CT, Siena S, Gianni AM. Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Ther. 1998; 5 (4): 465 - 72
30. Citterio G, Fragasso G, Rossetti E, Di Lucca G, Bucci E, Foppoli M, Guerrieri R, **Matteucci P**, Polastri D, Scaglietti U, Tresoldi M, Chierchia SL, Rugarli C. Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity. J Immunother Emphasis Tumor Immunol. 1996; 19 (2); 134 - 41
31. Fortis C, Galli L, Consogno G, Citterio G, **Matteucci P**, Scaglietti U, Bucci E. Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-

alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol. 1995; 76 (2):142 – 7

32. **Matteucci P**, Tresoldi M, Chiesa G, Tognella S, Citterio G, Fortis C, Besana C, Rugarli C. Intrapleural administration of interleukin-2 and LAK cells in locally advanced non-small-cell lung cancer. A case report. Tumori 1994; 80 (3): 246 - 50

